Baird Capital and Syndicate Invest in GreenLight Biosciences
January 8, 2019
Baird Capital invested in GreenLight Biosciences as part of a $50 million funding round led by S2G Ventures to scale the company's RNA production platform for agricultural and life-science applications. The capital will support expansion of GreenLight's scalable, low-cost RNA manufacturing capabilities and enable entry/expansion into pharmaceutical and crop-protection markets.
- Buyers
- Baird Capital, S2G Ventures, Fall Line Capital
- Targets
- GreenLight Biosciences, Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
LoneTree Capital Makes $23M Growth Investment in Northern Light Group
January 7, 2025
Cloud & SaaS
LoneTree Capital has made a $23 million growth investment in Boston-based Northern Light Group to accelerate product innovation and scale its enterprise knowledge management platform globally. As part of the investment, LoneTree partners Mike Devine, Rhett Lambert and Peter Bozian will join Northern Light's board; terms were not disclosed.
-
Bain Capital Life Sciences Leads $200M Growth Investment in Serán Bioscience
September 17, 2024
Pharmaceuticals
Bain Capital Life Sciences led a strategic growth investment of more than $200 million in Serán Bioscience, with existing investor Vivo Capital remaining a key shareholder. The capital will fund a new commercial-scale manufacturing campus in Bend, Oregon, expanding Serán's development, analytical and commercial manufacturing capabilities across multiple drug delivery modalities.
-
Baird Capital Invests in UGSI Solutions
June 15, 2022
Environmental Services
Baird Capital's private equity team has made an investment in UGSI Solutions, a provider of water quality management technologies and chemical feed systems for municipal and industrial clients. As part of the deal, Baird partners joined UGSI's board to support growth and operational improvements; financial terms were not disclosed.
-
Baird Capital Invests in Azzur Group
April 26, 2021
Healthcare Services
Baird Capital’s private equity team has made a growth investment in Azzur Group to accelerate expansion of the company’s early‑phase life science services, including Azzur Cleanrooms on Demand. Financial terms were not disclosed; Baird Capital advisors Brett Tucker and Dave Schroeder joined Azzur’s board and Gary Knight joined as an independent director. Brown Gibbons Lang & Company served as Azzur’s financial advisor and Edgemont Partners advised Baird Capital.
-
Baird Capital Leads $21M Series B in Jumpcode Genomics
January 12, 2021
Biotechnology
Baird Capital’s venture team led a $21 million Series B investment in Jumpcode Genomics, joined by Arboretum Ventures and existing investor LYZZ Capital. The funding will support Jumpcode’s CRISPRclean technology to improve next-generation sequencing sensitivity and advance applications across research and clinical diagnostics.
-
Baird Capital Invests in Blue Matter Consulting
September 1, 2020
Healthcare Services
Baird Capital, the private investment arm of Robert W. Baird & Co., has made a growth investment in Blue Matter Consulting LLC, a life sciences strategy consulting firm. The capital will support Blue Matter’s growth plans, including accelerating organic expansion and enabling potential strategic acquisitions; financial terms were not disclosed.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.